Genomic Health Announces New Evidence Further Demonstrating Clinical Utility and Cost-Effectiveness of Oncotype DX in Colon

 Genomic Health Announces New Evidence Further Demonstrating Clinical Utility
            and Cost-Effectiveness of Oncotype DX in Colon Cancer

Data Presented at the 2013 Gastrointestinal Cancers Symposium Show Test
Significantly Changes Treatment Decisions, May Reduce Medical Costs While
Increasing Patient Well-Being

Journal of Clinical Oncology Accepts for Publication Second Successful
Validation Study Confirming Oncotype DX Colon Cancer Test Provides Value
Beyond Conventional Markers

PR Newswire

REDWOOD CITY, Calif., Jan. 23, 2013

REDWOOD CITY, Calif., Jan. 23, 2013 /PRNewswire/ --Genomic Health, Inc.
(Nasdaq: GHDX) today announced results from three studies of the Oncotype DX^®
Colon Cancer test at the 2013 Gastrointestinal (GI) Cancers Symposium,
including new data demonstrating that Recurrence Score^® (RS) results changed
treatment recommendations in 45 percent of the enrolled stage II colon cancer
patients. Presentations also include positive findings from a second health
economics analysis suggesting that use of the test may result in a significant
reduction in direct medical costs and improve patient well-being.

Additionally, the company announced that the Journal of Clinical Oncology
(JCO) has accepted for publication results from its second large clinical
validation study of stage II colon cancer patients enrolled in CALGB 9581
confirming that the Oncotype DX test improves the ability to differentiate
higher from lower recurrence risk beyond conventional factors.

"These new data reinforce the value of an individualized recurrence risk
assessment score that enables physicians to identify those at high risk of
recurrence who can experience a greater potential benefit from chemotherapy,
as well as patients with a low risk of recurrence who can be spared
unnecessary treatment," said Steven Shak, M.D., chief medical officer and
executive vice president for research and development at Genomic Health.
"Oncotype DX represents an important advance in bringing personalized medicine
into the modern paradigm for cancer care. With a growing body of evidence,
and a second publication in JCO, we now have expanded support for broader
reimbursement and increased patient access to  our colon cancer test."

Oncotype DX Colon Cancer Test Changes 45 Percent of Treatment Decisions

"Current clinical practice reveals a high level of variability and
subjectivity in the treatment of stage II colon cancer patients," said Steven
Alberts, M.D., medical director for the Clinical Research Office in the Mayo
Clinic Cancer Center, Rochester, Minn. "The Oncotype DX Colon Cancer test
changes the paradigm for predicting individual recurrence risk for stage II
colon cancer patients by providing quantitative information which has not been
available with conventional measures."

    oConducted in collaboration with the Mayo Clinic Cancer Research
      Consortium, a prospectively designed study analyzed treatment decisions
      for 141 stage II, T3 MMR-proficient colon cancer patients across 17
      sites demonstrating that the use of the Oncotype DX Colon Cancer test
      changed treatment decisions 45 percent of the time and led to an overall
      reduction in chemotherapy use.

    For patients whose treatment recommendations changed, treatment intensity
    decreased for more than 33 percent of patients (from chemotherapy to
    observation or from oxaliplatin-containing to non-oxaliplatin containing
    regimens) and increased for more than 11 percent of patients (from
    observation to any chemotherapy or from non-oxaliplatin containing to
    oxaliplatin-containing treatment).

    Abstract #453: "Prospective evaluation of a 12-gene assay on treatment
    recommendations in stage II colon cancer patients" will be presented on
    Saturday, January 26, from 7:00–7:55 a.m. Pacific Time at Moscone West,
    San Francisco, Calif.

Second Health Economics Study Reconfirms Test's Cost Effectiveness

    oAn analysis of 141 patients from 17 sites in the Mayo Clinic Cancer
      Research Consortium demonstrated the value of using the Oncotype DX test
      to identify stage II colon cancer patients with low risk of recurrence.
      After receiving the Recurrence Score results, physician recommendations
      for adjuvant chemotherapy in patients with low risk of recurrence
      decreased by 22 percent, which resulted in direct medical care costs
      savings of $4,200 per patient.

    This is the first health economic study of the Oncotype DX Colon Cancer
    test conducted in clinical practice. A separate modeling study showing
    that the use of the Oncotype DX test in stage II colon cancer patients may
    lead to health care cost savings while improving clinical outcomes was
    recently published in the December 2012 issue of Value of Health.

    Abstract #391: "Real-world comparative economics of a 12-gene assay for
    prognosis in stage II colon cancer" will be presented on Saturday, January
    26, from 7:00–7:55 a.m. Pacific Time at Moscone West, San Francisco,
    Calif.

Additionally, the company will present a poster titled: "Impact of the
Recurrence Score (RS) result and mismatch repair status (MMR) on agreement
between oncologists (MDs) for stage II colon cancer (CC) recurrence risk (RR)
assessment: A novel clinical utility endpoint for prognostic markers"
(Abstract #349) on Saturday, January 26, from 7:00 – 7:55 a.m. Pacific Time at
Moscone West, San Francisco, Calif.

Four leading medical specialty societies co-sponsor the three-day,
multidisciplinary symposium, including the American Gastroenterological
Association Institute, the American Society of Clinical Oncology, the American
Society for Radiation Oncology and the Society of Surgical Oncology (SSO).

AboutGenomic Health

Genomic Health, Inc. (NASDAQ: GHDX) is a global healthcare company that
provides actionable genomic information to personalize cancer treatment
decisions. The company's lead product, the Oncotype DX^® breast cancer test,
has been shown to predict the likelihood of chemotherapy benefit as well as
recurrence in invasive breast cancer and has been shown to predict the
likelihood of recurrence in ductal carcinoma in situ (DCIS). In addition to
this widely adopted test, Genomic Health provides the Oncotype DX Colon Cancer
test, the first multi-gene expression test developed for the assessment of
risk of recurrence in patients with stage II and stage III disease. As of
September 30, 2012, more than 10,000 physicians in over 65 countries had
ordered more than 320,000 Oncotype DX tests. Genomic Health has a robust
pipeline focused on developing tests to optimize the treatment of prostate and
renal cell cancers, as well as additional treatment decisions in breast and
colon cancers. The company is based in Redwood City, California with European
headquarters in Geneva, Switzerland. For more information, please visit,
www.GenomicHealth.com. To learn more about the Oncotype DX tests, visit:
www.OncotypeDX.com and www.mybreastcancertreatment.org.

This press release contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995, including statements
relating to the ability of the company's colon cancer test to impact treatment
decisions in a clinical setting; the ability of test to reduce the use of
chemotherapy and the direct medical costs associated with treating colon
cancer; the potential of the company's test to change medical practice in the
treatment of stage II or stage III colon cancer; the ability of the company to
secure additional reimbursement for its colon cancer test; the applicability
of study results to clinical practice; the timing and results of future
studies or clinical trials; the focus and attributes of the company's product
pipeline; the ability of the company to develop additional tests in the
future; and the ability of any potential tests the company may develop to
optimize cancer treatment. Forward-looking statements are subject to risks and
uncertainties that could cause actual results to differ materially and
reported results should not be considered as an indication of future
performance. These risks and uncertainties include, but are not limited to:
the applicability of clinical study results to actual outcomes; the risks and
uncertainties associated with possible additional regulation of the company's
tests both in the United States and abroad; the availability and extent of
reimbursement coverage; risks associated with the commercialization of current
and future tests; the risks associated with competition; unanticipated costs
or delays in research and development efforts; and the other risks set forth
in the company's filings with the Securities and Exchange Commission,
including the risks set forth in the company's Quarterly Report on Form 10-Q
for the quarter ended September 30, 2012. These forward-looking statements
speak only as of the date hereof. Genomic Health disclaims any obligation to
update these forward-looking statements.

NOTE: The Genomic Health logo, Oncotype, Oncotype DX, Recurrence Score, and
DCIS Score are trademarks or registered trademarks of Genomic Health, Inc. All
other trademarks and service marks are the property of their respective
owners. 

SOURCE Genomic Health, Inc.

Website: http://www.genomichealth.com
Contact: Investors: Dean Schorno, Genomic Health, +1-650-569-2281,
investors@genomichealth.com; Media: Victoria Steiner, Genomic Health,
+1-415-370-5804, media@genomichealth.com
 
Press spacebar to pause and continue. Press esc to stop.